Carbohydrate Antigen 19-9 Predicts Synchronous Peritoneal Carcinomatosis in Patients with Colorectal Cancer.
Colorectal cancer (CRC) with peritoneal carcinomatosis (PC) has the worst prognosis among all types of metastases, but is difficult to diagnose. This study investigated whether preoperative serum carbohydrate antigen (CA) 19-9 level can predict synchronous PC in patients with primary CRC.



The cases of 395 CRC patients who underwent primary lesion resection were retrospectively reviewed. Risk factors were evaluated by uni- and multivariate analyses from clinicopathological data.



In the univariate analysis, tumor invasion (p<0.001), lymph node and hematogenous metastases (p=0.037 and p<0.001, respectively), and elevated preoperative serum CA19-9 level (p<0.001) were associated with synchronous PC, and multiple regression analysis revealed that an elevated preoperative serum CA19-9 level was an independent risk factor for PC (odds ratio=5.03, 95% confidence interval=1.29-19.60, p=0.020).



Elevated preoperative serum CA 19-9 level may be useful in predicting synchronous PC in patients with CRC.
Department of Surgery, Omori Red Cross Hospital, Tokyo, Japan m.kaneko@fancy.ocn.ne.jp.|Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Manabu
M
Kaneko
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Soichiro
S
Ishihara
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Koji
K
Murono
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Kazuhito
K
Sasaki
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Kensuke
K
Otani
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Koji
K
Yasuda
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Takeshi
T
Nishikawa
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Toshiaki
T
Tanaka
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Tomomichi
T
Kiyomatsu
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Keisuke
K
Hata
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Kazushige
K
Kawai
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroaki
H
Nozawa
Department of Surgery, Omori Red Cross Hospital, Tokyo, Japan.
Hiroshi
H
Nakayama
Department of Surgery, Omori Red Cross Hospital, Tokyo, Japan.
Toshiyuki
T
Watanabe
Department of Surgery, Omori Red Cross Hospital, Tokyo, Japan.
Shin
S
Sasaki
Department of Surgical Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Toshiaki
T
Watanabe
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018395:CA-19-9 Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009378:Neoplasms, Multiple Primary / Q000097:blood* / Q000175:diagnosis; D010534:Peritoneal Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000556:secondary; D057234:Preoperative Period; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors
D018395:CA-19-9 Antigen
Carbohydrate antigen 19-9; colorectal cancer; peritoneal carcinomatosis; risk factor